Literature DB >> 16750456

Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study.

Jianguo Li1, June Zhao, Jennifer E Hamer-Maansson, Tommy Andersson, Rose Fulmer, Marta Illueca, Per Lundborg.   

Abstract

OBJECTIVE: The aim of this study was to assess the pharmacokinetic (PK) properties and tolerability of esomeprazole 20 and 40 mg after single and repeated oral doses in adolescents with symptoms of gastroesophageal reflux disease (GERD).
RESULTS: The study included 15 boys and 13 girls (mean age, 14.3 years). Geometric mean AUC(0-infinity) values (overall drug exposure) were 1.58 and 5.57 micromol . h/L (0.027 and 0.083 pmol x h x L(-1)/kg) after single-dose administration of esomeprazole 20 and 40 mg, respectively, on day 1. Corresponding values with repeated doses (day 8) were 3.65 and 13.86 micromol x h/L (0.064 and 0.207 micromol x h x L(-1)/kg). Geometric mean Cmax values were 0.67 and 2.78 micromol/L (0.012 and 0.041 micromol/L x kg(-1)) with single-dose administration of esomeprazole 20 and 40 mg, respectively, and 1.45 and 5.13 micromol/L (0.026 and 0.075 micromol/L x kg(-1)), respectively, with repeated doses (day 8). These mean AUC(0-infinity) and CmaX values were >2-fold with the 40 mg dose compared with the 20-mg dose with single- and repeated-dose administration. The most common adverse event was headache (2 [7.1%] patients).
CONCLUSIONS: The results of this study suggest that the PK parameters of esomeprazole were both dose- and time-dependent in these adolescents with GERD. Both doses of esomeprazole were well tolerated in this study population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750456     DOI: 10.1016/j.clinthera.2006.03.010

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  11 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

Review 2.  Esomeprazole: in gastroesophageal reflux disease in children and adolescents.

Authors:  Jamie D Croxtall; Caroline M Perry; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 3.  Gastroesophageal reflux disease in children and adolescents: when and how to treat.

Authors:  Matthew W Carroll; Kevan Jacobson
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

Review 4.  Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.

Authors:  Shlomi Cohen; Mirjam Bueno de Mesquita; Francis B Mimouni
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

5.  Treatment options in pediatric GERD.

Authors:  Neelesh A Tipnis; Colin D Rudolph
Journal:  Curr Treat Options Gastroenterol       Date:  2007-10

Review 6.  Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children.

Authors:  Eric Hassall
Journal:  Curr Gastroenterol Rep       Date:  2008-06

7.  Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants.

Authors:  Hamid Reza Azizollahi; Mandana Rafeey
Journal:  Korean J Pediatr       Date:  2016-05-31

8.  A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Jason A Dare; Megan Francis-Sedlak; Julie Ball; Brian D LaMoreaux; Emily Von Scheven; Adam Reinhardt; Rita Jerath; Oral Alpan; Ramesh Gupta; Donald Goldsmith; Andrew Zeft; Henry Naddaf; Beth Gottlieb; Lawrence Jung; Robert J Holt
Journal:  Pediatr Rheumatol Online J       Date:  2018-06-26       Impact factor: 3.054

9.  Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.

Authors:  Giovanni Tafuri; Francesco Trotta; Hubert G M Leufkens; Nello Martini; Luciano Sagliocca; Giuseppe Traversa
Journal:  Eur J Clin Pharmacol       Date:  2008-09-17       Impact factor: 2.953

Review 10.  Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.

Authors:  Robert M Ward; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.